EIF4G3 Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HT29 colorectal adenocarcinoma cell line, designed for studying the role of the EIF4G3 scaffold protein in translation initiation and cancer biology. The polyclonal population contains a heterogeneous mixture of EIF4G3 gene disruptions, avoiding clonal artifacts and reflecting the functional consequences of EIF4G3 loss across a diverse cellular pool.
HT29 is a human epithelial-like cell line originating from a primary colorectal adenocarcinoma, widely employed as a model for intestinal epithelial biology, drug transport, and cancer research. The cells exhibit adherent growth and retain characteristics such as the ability to differentiate under specific culture conditions, making them suitable for functional genomics studies.
EIF4G3 encodes a scaffolding protein that bridges eIF4E and eIF4A within the eIF4F translation initiation complex, facilitating ribosome recruitment and cap-dependent mRNA translation. This process is regulated by the mTORC1 pathway through 4E-BP1 phosphorylation, and integrates signals from MAPK/ERK and MNK kinases. EIF4G3 interacts with eIF4E, eIF4A, eIF3, PABPC1, and other eIF4G family members to govern the translation of mRNAs with complex 5?? UTRs, including oncogenic transcripts such as c-MYC, CCND1, BCL2, and VEGFA. Its disruption therefore impinges on key nodes in translation control and cell growth.
In colorectal cancer cells like HT29, EIF4G3 is positioned to influence proliferation and survival through the PI3K/AKT/mTOR signaling axis. Knockout of EIF4G3 in this polyclonal population is expected to impair cap-dependent translation initiation, reducing synthesis of proteins that drive tumorigenic phenotypes. This model enables investigation of translation-dependent oncogenic mechanisms and the evaluation of therapeutic strategies targeting the translation machinery.
Researchers can utilize these polyclonal knockout cells in a variety of assays, including Western blotting to confirm protein loss, polysome profiling to assess translation status, and functional assays such as cell proliferation, colony formation, and apoptosis analysis by flow cytometry. Translation-specific readouts like m7GTP cap-binding assays and dual-luciferase reporters can quantify translation efficiency, while RT-qPCR verifies transcript-level changes. These cells are valuable for dissecting the role of EIF4G3 in colorectal cancer, viral IRES-mediated translation, and stress granule dynamics. For additional technical information, please contact Ascent Research.
